XTX Topco Ltd Acquires New Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

XTX Topco Ltd acquired a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 45,089 shares of the company’s stock, valued at approximately $126,000. XTX Topco Ltd owned 0.09% of Kodiak Sciences at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $902,000. Vontobel Holding Ltd. acquired a new position in shares of Kodiak Sciences during the first quarter valued at approximately $28,000. GSA Capital Partners LLP increased its stake in shares of Kodiak Sciences by 163.6% during the first quarter. GSA Capital Partners LLP now owns 205,833 shares of the company’s stock valued at $577,000 after acquiring an additional 127,748 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Kodiak Sciences by 5.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 521,237 shares of the company’s stock valued at $5,186,000 after acquiring an additional 26,058 shares during the period. Finally, Nantahala Capital Management LLC increased its stake in shares of Kodiak Sciences by 287.2% during the fourth quarter. Nantahala Capital Management LLC now owns 266,613 shares of the company’s stock valued at $2,653,000 after acquiring an additional 197,756 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $10.04 on Friday. The firm has a market cap of $529.71 million, a price-to-earnings ratio of -2.64 and a beta of 2.41. Kodiak Sciences Inc. has a 1 year low of $1.92 and a 1 year high of $11.60. The firm’s 50 day moving average price is $5.45 and its two-hundred day moving average price is $4.42.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.02). As a group, equities analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on KOD shares. Barclays raised their price objective on shares of Kodiak Sciences from $4.00 to $7.00 and gave the company an “underweight” rating in a research note on Thursday. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price target on the stock in a research report on Thursday.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.